American Society of Hematology

SHERPA: Blue

People

  1. Dogan
    Dogan
  2. Horwitz
    Horwitz
  3. Moskowitz
    Moskowitz
  4. Zelenetz
    Zelenetz
  5. Kumar
    Kumar
  6. Palomba
    Palomba
  7. Noy
    Noy
  8. Roshal
    Roshal
  9. Hamlin
    Hamlin
  10. Arcila
    Arcila

Groups

  1. Department of Pathology and Laboratory Medicine (147)
  2. Department of Medicine (130)
  3. Hematologic Malignancies, Division of (130)
  4. Center for Hematologic Malignancies (128)
  5. Hematology-Oncology Fellows (84)
  6. Lymphoma (80)
  7. Sloan Kettering Institute Postdocs (74)
  8. GSK Faculty (63)
  9. Population Sciences Research Program (62)
  10. Survivorship Research (61)
Search Within
  1. "Ahmet Dogan"
Formats
  1. Meeting Abstract (115)
  2. Journal Article (28)
  3. Research Letter (2)
  4. Guidelines (1)
  5. Review (1)
Groups
  1. Department of Pathology and Laboratory Medicine (147)
  2. Department of Medicine (130)
  3. Hematologic Malignancies, Division of (130)
  4. Center for Hematologic Malignancies (128)
  5. Hematology-Oncology Fellows (84)
  6. Lymphoma (80)

More Groups

People
  1. Ahmet Dogan (147)
  2. Steven Horwitz (50)
  3. Alison Moskowitz (48)
  4. Andrew Zelenetz (48)
  5. Anita Kumar (39)
  6. Maria Palomba (38)

More People

Years
  1. 2025 (1)
  2. 2024 (18)
  3. 2023 (15)
  4. 2022 (15)
  5. 2021 (16)
  6. 2020 (13)

More Years

Publications
  1. Blood (135)
  2. Blood Advances (12)

Results (147)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Defining 2 biologically and clinically distinct groups in acute leukemia with a mixed phenotype
    Journal Article

    Galera, P.; Dilip, D.; Derkach, A.; Chan, A.; Zhang, Y.; Persaud, S.; Mishra, T.; Kramer, K.; Kathpalia, M.; Liu, Y.; more...
    Blood (2025)

    Fulltext@MSK | Save
  • Sequential R-CHOP/(R)-ICE and dose-adjusted EPOCH-R are both appropriate frontline treatments for newly diagnosed primary mediastinal B-cell lymphoma: Results of a retrospective analysis
    Meeting Abstract

    Bantilan, K. S.; Luttwak, E.; Moskowitz, C. H.; Matasar, M.; Straus, D. J.; Portlock, C. S.; Moskowitz, A.; Noy, A.; Palomba, M. L.; Horwitz, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Angioimmunoblastic versus non-angioimmunoblastic nodal T-follicular helper cell lymphomas: Single center retrospective analysis on 208 cases
    Meeting Abstract

    Sordi, B.; Eren, O. C.; Ganesan, N.; Iyengar, V.; Stuver, R.; Johnson, W. T.; Moskowitz, A.; Ghione, P.; Galasso, N.; Casper, E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab and involved site radiation therapy alone as an alternative to transplant in patients with localized failure following chemotherapy for Hodgkin Lymphoma: A prospective multicenter phase II study
    Meeting Abstract

    Dreyfuss, A.; Ganesan, N.; Alencar, A. J.; Boardman, A. P.; Caron, P.; Chang, T.; Davey, T.; David, K. A.; Dogan, A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Improved outcomes for primary refractory classical Hodgkin Lymphoma: A retrospective analysis
    Meeting Abstract

    Santarosa, A. M.; Ganesan, N.; Chang, T.; Hannigan, K.; Casper, E.; Shah, G. L.; Boardman, A. P.; Caron, P.; David, K. A.; Dogan, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Peripheral blood smear-based deep learning to predict cancer-associated thrombosis
    Meeting Abstract

    Dilip, D.; Singi, S.; Webb, D. C.; Colorado-Jimenez, C.; Singh, R.; Yin, Z.; Paulsen, S.; McVoy, L.; Fenelus, M.; Roshal, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naive chronic lymphocytic leukemia: 5-Year follow up, retreatment outcomes, and Impact of MRD kinetics (ΔMRD400)
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K. L.; Slupe, N.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Genomic characterization and classification of BCL6 rearranged follicular lymphomas
    Meeting Abstract

    Amallraja, A.; Gundem, G.; Domenico, D.; Ossa, J. E. A.; Aypar, U.; Baik, J.; Kluk, M.; Sethi, S.; Lopez, K.; Qualls, D. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • High grade B-cell lymphoma with MYC/BCL6-rearrangements (R) may have inferior outcomes compared to BCL2-R disease
    Meeting Abstract

    Healton, S. E.; Luttwak, E.; Rivas-Delgado, A.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Adult AML patients with NUP98 fusions are frequently therapy-related, and are associated with monocytic differentiation, recurring mutations in NRAS, DNMT3A and WTI and poor outcome
    Meeting Abstract

    Yao, J.; Aypar, U.; Sethi, S.; Boussi, L.; Londono, D.; Sukhadia, P.; Berman, E.; Stein, E. M.; Dogan, A.; Xiao, W.; more...
    Blood (2024)

    Fulltext@MSK | Save